Skip to content. | Skip to navigation


Personal tools

Research Team

Scientists

 

Dr. Brad Nelson, PhD

Brad Lab 2

Dr. Nelson received training at the University of California at Berkeley (Ph.D.) and Fred Hutchinson Cancer Research Center (postdoc), and in 2003 became founding Director of the Deeley Research Centre.  His laboratory is pursuing the development of immune-based therapies for cancer.  Areas of focus include: understanding how tumour-reactive T cells and B cells promote patient survival in cancer; defining the effects of standard treatments on tumor immunity; and using genomic approaches to identify novel tumour mutations that can serve as target antigens for immunotherapy.                               


 Dr. Peter Watson, MB BChir FRCPC

Peter Lab 1

Dr. Watson began his medical training at the University of Cambridge and St. Thomas' Hospital and completed specialty training in Pathology at the University of Manitoba, where he served on faculty from 1993.  He joined the BC Cancer Agency in 2005 to become the Director of the Tumour Tissue Repository and more recently Chief Physician of the Vancouver Island Centre in 2009.   Dr. Watson has a long-standing interest in the molecular pathology and biomarkers of breast cancer.  His laboratory has pioneered work on S100A7 and its role in breast cancer progression. 

Dr. Julian Lum,  PhD

Julian Lab 2

Dr. Lum obtained his Ph.D. from the University of Ottawa and pursued a post-doctoral fellowship at the University of Pennsylvania.  His research program is interested in understanding how cellular metabolism regulates tumorigenesis.  He is studying how autophagy promotes tumour cell survival and studying whether these pathways can be used as novel targets for T cell therapy.  Other areas include: cancer stem cells, metabolic control of T cells, and immunotherapy.


 Project Leaders

Dr. John Webb, PhD

John Lab 1Dr. Webb completed his graduate training at the University of British Columbia and spent several years working in industry before becoming a faculty member at the University of Ottawa.  Following this, he returned to industry and developed an interest in vaccines for human malignancies.  Dr. Webb joined the Deeley Research Centre as the T cell Projects Leader continuing his work in cancer immunotherapy.  In addition, Dr. Webb has been studying new vaccine strategies to induce T cell-mediated immune responses.

  Clinical collaborators

Howard H. Pai, MD FRCPC

Dr. Pai received his Medical degree at the University of Western Ontario (1993) and completed specialty training in Radiation Oncology at McGill University in Montreal (1997).  He completed fellowship training in proton radiotherapy at Massachusetts General Hospital/Harvard Medical School in Boston Massachusetts in 1998.  He is a radiation oncologist at the BC Cancer Agency - Vancouver Island Centre, sub-specializing in cancers of the genitourinary, gastrointestinal and central nervous systems. Dr. Pai holds faculty appointments in the Department of Surgery, Faculty of Medicine at the University of British Columbia and in the Departments of Health Information Science and Medicine at University of Victoria.  His current research interests include prostate cancer, patient support, health informatics, clinical trials and radioimmunology.

Nicol MacPherson, MD PhD FRCPC

Dr. Nicol Macpherson is a medical oncologist at the BC Cancer Agency (Vancouver Island Centre) with a special interest in breast cancer and lymphomas.  He obtained his MD from Queen's University at Kingston and his PhD in Pathobiology and Laboratory Medicine at the University of Toronto.  Internal medicine training was completed at the University of Toronto, and Medical Oncology training at the University of British Columbia.  His research interests include the development of immune-based therapies to treat lymphomas, and strategies to reverse or delay resistance to hormone therapy in breast cancer. 

Paul Blood, BM  PhD FRCPC

Dr. Blood completed his under-graduate training in England and his post-graduate training in radiation oncology in Manitoba.  He completed a Ph.D. in epidemiology at UBC.  His clinical areas include genitourinary, gastrointestinal, and lung cancers.  His research interests include clinical outcomes research in prostate cancer using population healthcare databases.